Filtered By:
Condition: Thrombosis
Vaccination: Vaccines

This page shows you your search results in order of date.

Order by Relevance | Date

Total 145 results found since Jan 2013.

PAD4-Induced NETosis Via Cathepsin G-Mediated Platelet-Neutrophil Interaction in ChAdOx1 Vaccine-Induced Thrombosis
CONCLUSIONS: Patients with VITT display enhanced thrombogenesis by PAD4-mediated NETs formation via cathepsin G-mediated platelet/neutrophil interaction.PMID:37586040 | DOI:10.1161/ATVBAHA.123.319522
Source: Arteriosclerosis, Thrombosis and Vascular Biology - August 16, 2023 Category: Cardiology Authors: Roberto Carnevale Martina Leopizzi Marcello Dominici Giulia d'Amati Simona Bartimoccia Cristina Nocella Vittoria Cammisotto Alessandra D'Amico Valentina Castellani Francesco Baratta Alessia Bertelli Alessio Arrivi Danilo Toni Manuela De Michele Pasquale P Source Type: research

Outcomes After Decompressive Surgery for Severe Cerebral Venous Sinus Thrombosis Associated or Not Associated with Vaccine-Induced Immune Thrombosis with Thrombocytopenia: A Multicenter Cohort Study
ConclusionsAlthough the prediction of individual courses remains challenging, DS should be considered early in VITT-associated CVST because an overall favorable outcome appears achievable in these patients.
Source: Neurocritical Care - July 27, 2023 Category: Neurology Source Type: research

Influenza vaccination and cardiovascular events in patients with ischaemic heart disease and heart failure: A meta ‐analysis
ConclusionIn this meta-analysis of available RCTs in patients at high cardiovascular risk, influenza vaccination was associated with a reduced incidence of cardiovascular events, cardiovascular death and all-cause death as compared to placebo or no treatment.
Source: European Journal of Heart Failure - June 28, 2023 Category: Cardiology Authors: Daniel Modin, Mats Christian H øjbjerg Lassen, Brian Claggett, Niklas Dyrby Johansen, Maryam Keshtkar‐Jahromi, Kristoffer Grundtvig Skaarup, Joshua Nealon, Jacob A. Udell, Orly Vardeny, Scott D. Solomon, Gunnar Gislason, Tor Biering‐Søren Tags: Research Article Source Type: research

Neuro-Ophthalmic Visual Impairment in the Setting of COVID-19
We describe and elaborate on mechanisms of disease, including para-infectious inflammation, hypercoagulability, endothelial damage, and direct neurotropic viral invasion. Despite global vaccination programs, new variants of COVID-19 continue to pose an international threat, and patients with rare neuro-ophthalmic complications are likely to continue to present for care.Afferent complications from COVID-19 include homonymous visual field loss, with or without higher cortical visual syndromes, resulting from stroke, intracerebral hemorrhage, or posterior reversible leukoencephalopathy. Optic neuritis has frequently been repo...
Source: Seminars in Neurology - June 13, 2023 Category: Neurology Authors: Dinkin, Marc Sathi, Swetha Tags: Review Article Source Type: research

Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
RARITAN, NJ, May 25, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor (being developed in collaboration with Bristol Myers Squibb), have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients. The Librexia program is unrivaled as the most comprehensive FXIa clinical...
Source: Johnson and Johnson - May 25, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Viruses, Vol. 15, Pages 1235: Ischaemic Stroke Occurring in a Patient Treated with Monoclonal Antibodies for COVID-19
In conclusion, among several side effects that have been described during the treatment of COVID-19 with sotrovimab, ischaemic stroke was not reported. Therefore, we here report a rare case of ischaemic stroke with early clinical manifestation after the administration of sotrovimab for the treatment of moderate COVID-19 in an immunocompromised patient for the first time.
Source: Viruses - May 25, 2023 Category: Virology Authors: Antonio Lobasso Ciro di Gennaro Maria Rita Poggiano Antonio Vasta Raffaele Angelo Nicola Ranucci Roberto Lobianco Anna Giacoma Tucci Enrico Cavagli à Pierpaolo Di Micco Tags: Case Report Source Type: research

Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature
Ther Adv Drug Saf. 2023 May 21;14:20420986231165674. doi: 10.1177/20420986231165674. eCollection 2023.ABSTRACTAmid the coronavirus disease 2019 (COVID-19) pandemic, massive immunization campaigns became the most promising public health measure. During clinical trials, certain neurological adverse effects following immunization (AEFIs) were observed; however, acceptable safety profiles lead to emergency authorization for the distribution and use of the vaccines. To contribute to pharmacovigilance and lessen the potential negative impact that vaccine hesitancy would have on immunization programs, we conducted a review of the...
Source: Adv Data - May 24, 2023 Category: Epidemiology Authors: Sara Eslait-Olaciregui Kevin Llin ás-Caballero David Pati ño-Manjarrés Thomas Urbina-Ariza Juan Fernando Cediel-Becerra Camilo Alberto Dom ínguez-Domínguez Source Type: research

A case report overlapped vaccine and COVID-19 in disseminated atherosclerosis
Clin Exp Vaccine Res. 2023 Apr;12(2):172-175. doi: 10.7774/cevr.2023.12.2.172. Epub 2023 Apr 30.ABSTRACTCoronavirus disease 2019 (COVID-19) has become a part of our lives now and we have no more effective way of coping than a vaccine. COVID-19 is a disease that causes severe thrombosis outside the respiratory tract. Vaccines also protect us in this respect, but in some rare cases, thrombosis has been found to develop after vaccination (much less frequently than COVID-19). What was interesting in our case was that it showed how a disaster could happen under three factors that predispose to thrombosis. A 65-year-old female p...
Source: Atherosclerosis - May 22, 2023 Category: Cardiology Authors: Vecihe Bayrak Source Type: research

Medically Attended Acute Adverse Events in Pregnant People After Coronavirus Disease 2019 (COVID-19) Booster Vaccination
Obstet Gynecol. 2023 May 11. doi: 10.1097/AOG.0000000000005241. Online ahead of print.ABSTRACTIn this multisite, observational, matched cohort study of more than 80,000 pregnant people, receipt of an mRNA monovalent coronavirus disease 2019 (COVID-19) booster vaccination in pregnancy was not associated with increased risk for thrombocytopenia, myocarditis, venous thromboembolism, ischemic stroke, or other serious adverse events within 21 or 42 days after booster vaccination. The mRNA monovalent COVID-19 booster in pregnancy was associated with an increased risk for medically attended malaise or fatigue within 7 days of vac...
Source: Obstetrics and Gynecology - May 11, 2023 Category: OBGYN Authors: Malini B DeSilva Jacob Haapala Gabriela Vazquez-Benitez Thomas G Boyce Candace C Fuller Matthew F Daley Darios Getahun Simon J Hambidge Heather S Lipkind Allison L Naleway Jennifer C Nelson Kimberly K Vesco Eric S Weintraub Joshua T B Williams Ousseny Zer Source Type: research